A slimmer Diasonics turns profits

Article

Diasonics showed initial success last year in refocusing its medicalimaging business on ultrasound and specialty x-ray products, followingthe sale of its magnetic resonance imaging unit to Toshiba inlate 1989. The Milpitas, CA, company lowered its

Diasonics showed initial success last year in refocusing its medicalimaging business on ultrasound and specialty x-ray products, followingthe sale of its magnetic resonance imaging unit to Toshiba inlate 1989. The Milpitas, CA, company lowered its lithotripsy expectations,however, as market projections for that therapeutic modality sagged.

Diasonics now considers lithotripsy as largely an upgrade opportunityfor users of its Uroview urology x-ray system, said presidentRod Young.

"We view (lithotripsy) as mostly a renal market in theU.S.--and to a large extent, a replacement renal market. However,we are still doing a fair amount of business in Japan and otherinternational markets," Young said.

Japanese approval of biliary lithotripsy could come sometimethis year, which will increase the attractiveness of this market,he said.

Although U.S. ultrasound sales have not reached desired levels,Diasonics' overall revenue from continuing product lines grew37.5% last year, from $194 million in 1989 to $267 million. Companyincome--minus the lump-sum earnings from the sale of the MRI business--was$16.4 million for the year, compared to a loss from continuingoperations of $21.5 million in 1989 (see graph).

Diasonics hopes sales of its all-digital Spectra Plus color-Dopplerultrasound system, introduced last year, will boost 1991 revenues.The ultrasound business unit should also benefit from sales ofthe vendor's IVUS intraluminal ultrasound device. IVUS was approvedby the Food and Drug Administration for coronary and intracardiacimaging last year.

Nearly half (45%) of Diasonics' 1990 revenues came from internationalsales, generated largely through Sonotron, the vendor's Swisssubsidiary. Another 29% of revenue came from OEC Diasonics ofSalt Lake City, the vendor's x-ray unit.

International revenues were enhanced by a decline in the valueof the dollar last year. However, Sonotron's success selling VingmedSound's cardiovascular ultrasound system in Europe was also afactor in Diasonics' strong international performance. The firm'sVingmed business should increase this year following acquisitionof Vingmed Sound in the fourth quarter of 1990 (SCAN 12/12/90),Young said.

Although lithotripsy did not pan out as expected, Diasonicscontinues to invest in ways to leverage its imaging technologyinto therapeutic applications. On the front burner is a partnershipwith Paine Webber to develop an ultrasound-based ablation systemfor the treatment of benign prostatic hyperplasia, a disease characterizedby enlargement of the prostate.

This use of ultrasound waves to remove tissue could have futureapplications in other clinical areas, such as surgery and oncology,according to Diasonics literature.

Recent Videos
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
Related Content
© 2025 MJH Life Sciences

All rights reserved.